Sign up Australia
Proactive Investors - Run By Investors For Investors

Zelda Therapeutics expands pipeline of opportunities

Zelda is a California-founded biotech focused on medical cannabis therapies.
Zelda Therapeutics expands pipeline of opportunities
Today's agreement with help accelerate valuable research

Zelda Therapeutics (ASX:ZLD) continues to leverage world-class knowledge and expertise in the medical cannabis sector.

A new license agreement with Caziwell Inc increases flexibility to expand the clinical trial program.

The agreement provides significant immediate and long-term financial benefits for Zelda and replaces the existing agreement.

Harry Karelis, executive chairman for Zelda, commented:

“The restructuring of the Caziwell Licence Agreement provides a meaningful positive impact to Zelda shareholders by reducing future financial obligations it would have incurred through executing its clinical trials strategy.

"With these amendments in place, Zelda moves closer to industry standards for agreements of this nature.

"We have a full pipeline of opportunities ahead of us and reducing future expenses helps extend our financial capacity to progress these projects.

"We have a very exciting year ahead."


New license agreement benefits

- Zelda maintains exclusive access to patient data, formulations and protocols for use in its current research activities;
- Positive impact on cashflow, with an immediate $200,000 saving;
- Permanent reduction in future royalty and sub-licence fees; and
- Significantly increases flexibility to expand clinical trial program.


Trials

Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer.


World-leading Scientific Advisory Board

Prof. Manuel Guzman: Full Professor of Biochemistry and Molecular Biology at Madrid’s Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death.

Dr Cristina Sanchez: Assistant Professor at Complutense University, Madrid Spain. Specialist in the area of lipid signaling, including cannabinoids in an oncology setting.

Dr Joe Goldstrich: Distinguished clinical career in preventive cardiology and nutrition spanning over 40 years. He has evaluated over 3,500 patients in the US using cannabis as a fundamental medicine in the management of a variety of medical conditions.

Dr Noah Federman: Highly respected paediatric clinical and research oncologist. Currently, Director of the Paediatric Bone and Soft Tissue Sarcoma Program at University of California, part of the prestigious UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Centre.


Analysis

Zelda continues to expand its relationships and agreements in the sector.

The company has a strong background in medical cannabis, and was formed to fund clinical efficacy trials developed by its U.S. partner, Aunt Zelda, and used to treat a range of diseases showing strong efficacy data.

Investors are recognising the potential since the listing (via RTO) in November 2016, where shares could be purchased at $0.025 in the $4 million raising.

Since then Zelda has more than tripled in value, last trading at $0.085 per share.

View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
picture of human skeleton
January 16 2018
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln
picture of genes
November 29 2017
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use